Clinical significance of promoter hypermethylation of RASSF1A, RARβ2, BRCA1 and HOXA5 in breast cancers of Indian patients

Life Sciences

Volumn 82, Issue 25-26, 2008, Pages 1288-1292

  Bagadi, Sarangadhara Appala Raju ^a   Prasad, Chandra Prakash ^a   Kaur, Jatinder ^a   Srivastava, Anurag ^a   Prashad, Rajinder ^a   Gupta, Siddartha Datta ^a   Ralhan, Ranju ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

BRCA1; Breast cancer; HOXA5; Promoter hypermethylation; RAR 2; RASSF1A

Indexed keywords

BRCA1 PROTEIN; HORMONE RECEPTOR; HOXA5 PROTEIN; PROTEIN; RAR BETA2 PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; ARTICLE; BREAST CANCER; CARCINOGENESIS; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIAN; METASTASIS; PROMOTER REGION;

ADULT; AGED; BRCA1 PROTEIN; BREAST NEOPLASMS; DNA METHYLATION; FEMALE; GENES, NEOPLASM; HOMEODOMAIN PROTEINS; HUMANS; INDIA; MIDDLE AGED; PROMOTER REGIONS (GENETICS); RECEPTORS, RETINOIC ACID; TUMOR SUPPRESSOR PROTEINS;

EID: 44649187407     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.04.020     Document Type: Article

References (45)

1. Bae Y.K., Brown A., Garrett E., Bornman D., Fackler M.J., Sukumar S., Herman J.G., and Gabrielson E. Hypermethylation in histologically distinct classes of breast cancer. Clincal Cancer Research 10 18 Pt 1 (2004) 5998-6005
2. Bagadi S.A., Prasad C.P., Srivastava A., Prashad R., Gupta S.D., and Ralhan R. Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer. Breast Cancer Research and Treatment 104 3 (2007) 277-286
3. Birgisdottir V., Stefansson O.A., Bodvarsdottir S.K., Hilmarsdottir H., Jonasson J.G., and Eyfjord J.E. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Research 8 4 (2006) R38
4. Brisken C., Park S., Vass T., Lydon J.P., O'Malley B.W., and Weinberg R.A. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proceedings of the National Academy of Sciences of the United States of America 95 9 (1998) 5076-5081
5. Burbee D.G., Forgacs E., Zochbauer-Muller S., Shivakumar L., Fong K., Gao B., Randle D., Kondo M., Virmani A., Bader S., Sekido Y., Latif F., Milchgrub S., Toyooka S., Gazdar A.F., Lerman M.I., Zabarovsky E., White M., and Minna J.D. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. Journal of National Cancer Institute 93 9 (2001) 691-699
6. Catteau A., Harris W.H., Xu C.F., and Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18 11 (1999) 1957-1965
7. Chopra R. The Indian scene. Journal of Clinical Oncology 19 18 Suppl (2001) 106S-111S
8. Clark G.M., and McGuire W.L. Steroid receptors and other prognostic factors in primary breast cancer. Seminars in Oncology 15 2 Suppl 1 (1988) 20-25
9. Costello J.F., Plass C., and Cavenee W.K. Aberrant methylation of genes in low-grade astrocytomas. Brain Tumor Pathology 17 2 (2000) 49-56
10. Dammann R., Yang G., and Pfeifer G.P. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Research 61 7 (2001) 3105-3109
11. In: Elston C.W., and Ellis I.O. (Eds). Assessment of Histological Grade (1998), Churchill Livingstone, New York
12. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21 35 (2002) 5427-5440
13. Esteller M., Corn P.G., Baylin S.B., and Herman J.G. A gene hypermethylation profile of human cancer. Cancer Research 61 8 (2001) 3225-3229
14. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., Bussaglia E., Prat J., Harkes I.C., Repasky E.A., Gabrielson E., Schutte M., Baylin S.B., and Herman J.G. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. Journal of National Cancer Institute 92 7 (2000) 564-569
15. Fackler M.J., McVeigh M., Evron E., Garrett E., Mehrotra J., Polyak K., Sukumar S., and Argani P. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. International Journal of Cancer 107 6 (2003) 970-975
16. Feng W., Shen L., Wen S., Rosen D.G., Jelinek J., Hu X., Huan S., Huang M., Liu J., Sahin A.A., Hunt K.K., Bast Jr. R.C., Shen Y., Issa J.P., and Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Research 9 4 (2007) R57
17. Fiegl H., Millinger S., Mueller-Holzner E., Marth C., Ensinger C., Berger A., Klocker H., Goebel G., and Widschwendter M. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Research 65 4 (2005) 1141-1145
18. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences USA 93 18 (1996) 9821-9826
19. Honorio S., Agathanggelou A., Schuermann M., Pankow W., Viacava P., Maher E.R., and Latif F. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 22 1 (2003) 147-150
20. Issa J.P. Aging, DNA methylation and cancer. Critical Reviews in Oncology Hematology 32 1 (1999) 31-43
21. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nature Reviews Genetics 3 6 (2002) 415-428
22. Lawson J.S., Field A.S., Champion S., Tran D., Ishikura H., and Trichopoulos D. Low oestrogen receptor alpha expression in normal breast tissue underlies low breast cancer incidence in Japan. The Lancet 354 9192 (1999) 1787-1788
23. Maruyama R., Toyooka S., Toyooka K.O., Harada K., Virmani A.K., Zochbauer-Muller S., Farinas A.J., Vakar-Lopez F., Minna J.D., Sagalowsky A., Czerniak B., and Gazdar A.F. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Research 61 24 (2001) 8659-8663
24. Matros E., Wang Z.C., Lodeiro G., Miron A., Iglehart J.D., and Richardson A.L. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Research and Treatment 91 2 (2005) 179-186
25. Matsumoto K., Sakamoto G., and Nomura Y. International comparisons concerning breast cancer and steroid receptors. Anticancer Research 6 4 (1986) 621-624
26. McGuire W.L. Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Seminars in Oncology 5 4 (1978) 428-433
27. Mehrotra J., Ganpat M.M., Kanaan Y., Fackler M.J., McVeigh M., Lahti-Domenici J., Polyak K., Argani P., Naab T., Garrett E., Parmigiani G., Broome C., and Sukumar S. Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clincal Cancer Research 10 6 (2004) 2052-2057
28. Mehrotra J., Vali M., McVeigh M., Kominsky S.L., Fackler M.J., Lahti-Domenici J., Polyak K., Sacchi N., Garrett-Mayer E., Argani P., and Sukumar S. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clinical Cancer Research 10 9 (2004) 3104-3109
29. Mirza S., Sharma G., Prasad C.P., Parshad R., Srivastava A., Gupta S.D., and Ralhan R. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sciences 81 4 (2007) 280-287
30. Muller H.M., Fiegl H., Widschwendter A., and Widschwendter M. Prognostic DNA methylation marker in serum of cancer patients. Annals of New York Academy of Science 1022 (2004) 44-49
31. Muller H.M., Widschwendter A., Fiegl H., Ivarsson L., Goebel G., Perkmann E., Marth C., and Widschwendter M. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Research 63 22 (2003) 7641-7645
32. National Cancer Database. Annual Review of Patient Care (1993), American Cancer Society, Atlanta, GA
33. Niwa Y., Oyama T., and Nakajima T. BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. Japanese Journal of Cancer Research 91 5 (2000) 519-526
34. Osborne C.K., Yochmowitz M.G., Knight III W.A., and McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46 12 Suppl (1980) 2884-2888
35. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. Cancer Journal for Clinicians 55 2 (2005) 74-108
36. Raman V., Martensen S.A., Reisman D., Evron E., Odenwald W.F., Jaffee E., Marks J., and Sukumar S. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405 6789 (2000) 974-978
37. Raman V., Tamori A., Vali M., Zeller K., Korz D., and Sukumar S. HOXA5 regulates expression of the progesterone receptor. Journal of Biological Chemistry 275 34 (2000) 26551-26555
38. Rice J.C., and Futscher B.W. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Research 28 17 (2000) 3233-3239
39. Sharma G., Mirza S., Prasad C.P., Srivastava A., Gupta S.D., and Ralhan R. Promoter hypermethylation of p16(INK4A), p14(ARF), CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sciences 81 4 (2007) 280-287
40. Shukla S., Mirza S., Sharma G., Parshad R., Gupta S.D., and Ralhan R. Detection of RASSF1A and RAR beta hypermethylation in Serum DNA from breast cancer patients. Epigenetics 1 (2006) 88-93
41. Singletary S.E., Allred C., Ashley P., Bassett L.W., Berry D., Bland K.I., Borgen P.I., Clark G.M., Edge S.B., Hayes D.F., Hughes L.L., Hutter R.V., Morrow M., Page D.L., Recht A., Theriault R.L., Thor A., Weaver D.L., Wieand H.S., and Greene F.L. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surgicals of Clinicians of North America 83 4 (2003) 803-819
42. Widschwendter M., Berger J., Hermann M., Muller H.M., Amberger A., Zeschnigk M., Widschwendter A., Abendstein B., Zeimet A.G., Daxenbichler G., and Marth C. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. Journal of National Cancer Institute 92 10 (2000) 826-832
43. Widschwendter M., and Jones P.A. DNA methylation and breast carcinogenesis. Oncogene 21 35 (2002) 5462-5482
44. Yang Q., Mori I., Shan L., Nakamura M., Nakamura Y., Utsunomiya H., Yoshimura G., Suzuma T., Tamaki T., Umemura T., Sakurai T., and Kakudo K. Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer. American Journal of Pathology 158 1 (2001) 299-303
45. Yang Q., Sakurai T., Yoshimura G., Mori I., Nakamura M., Nakamura Y., Suzuma T., Tamaki T., Umemura T., and Kakudo K. Hypermethylation does not account for the frequent loss of the retinoic acid receptor beta2 in breast carcinoma. Anticancer Research 21 3B (2001) 1829-1833